Biontech SE expected to post earnings of 79 cents a share - Earnings Preview
Biontech SE , is expected to show a fall in quarterly revenue when it reports results on November 3 for the period ending September 30 2026
The Mainz Rheinland-pfalz-based company is expected to report a 30.6% decrease in revenue to €1.055 billion from €1.52 billion a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biontech SE is for earnings of 79 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biontech SE is $127.00, about 42.5% above its last closing price of $89.13
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -2.16 | -2.09 | -3.24 | Missed | -54.9 |
Mar. 31 2026 | -2.25 | -2.22 | -2.10 | Beat | 5.5 |
Dec. 31 2025 | 0.19 | -0.19 | -1.25 | Missed | -572.3 |
Sep. 30 2025 | -0.21 | -0.21 | -0.12 | Beat | 43.3 |
Jun. 30 2025 | -2.43 | -2.01 | -1.60 | Beat | 20.3 |
Mar. 31 2025 | -2.14 | -2.09 | -1.73 | Beat | 17.2 |
Dec. 31 2024 | 0.62 | 0.33 | 1.08 | Beat | 231.9 |
Sep. 30 2024 | -1.26 | -1.56 | 0.81 | Beat | 151.9 |
This summary was machine generated October 30 at 13:34 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)